Early Access — free while we kick the tires
EdgarHawk

OMIC Singular Genomics Systems, Inc. Insider Trading

1 filing analyzed · Latest 2024-09-18
Insider buys
1
Insider sells
0
Unique insiders
1
Direction
Net buying

Historically, high-priority insider buys have outperformed the S&P 500 by a median ~2% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 5,751, 2021-2026). Past results don't predict the future. How we measure this ↗

September 2024
2024-09-18
high
122,416 shares
$1,806,220
@ $14.75
Significance 6/10

10% owner Kevin Tang buys 122,416 shares for $1.8M across 3 transactions, raising stake to 372K shares amid 153.6% 30-day rally.

Kevin Tang, a 10% owner of Singular Genomics, executed 3 separate purchases totaling 122,416 shares for $1,806,219.84 between September 16–18, with a blended average price of $14.75, increasing his holdings by 49.0% to 372,000 shares. The timing coincides with pronounced positive price momentum: the stock has risen 153.6% over 30 days and 74.4% over 90 days, now trading at $16.79 near its 52-week high of $18.30. However, the company remains unprofitable ($-21.3M net income) with minimal trailing-quarter revenue ($737.0K), though it posted 280.5% annual revenue growth. Tang's own cross-ticker track record shows 20 prior buys with a 30.00% 90-day win rate and average 90-day return of -1.9%, suggesting his historical purchasing decisions have not consistently outperformed the market. The magnitude and timing of this accumulation warrant examination of what conditions or information motivated a 49% position increase during an already-elevated valuation period.

Insiders here also file at

More Measuring and Controlling Instruments companies

Get alerts for OMIC

Add OMIC to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access